Skip to main content
. 2014 Aug 18;2:15. doi: 10.1186/2050-7771-2-15

Table 2.

Distribution of genotype and allele frequencies in patients and in controls; in subgroup and in response to anti-VEGF

SNPs
  
 Patients n = 145
 Controls n = 207
 G1 n = 117
 G2 n = 28
 GR n = 52
 PR n = 16
    n (%) n (%) n (%) n (%) n (%) n (%)
(−2578)
 CC
 19 (13.10)
 38 (18.35)
 16 (13.67)
 3 (10.71)
 4 (7.7)
 4 (25)
 
 CA
 67 (46.21)
 88 (42.51)
 57 (48.71)
 10 (35.71)
 24 (46.1)
 9 (56.2)
 
 AA
 59 (40.69)
 81 (39.13)
 44 (37.60)
 15 (53.57)
 24 (46.1)***
 3 (18.8)
 
 C
 0.362
 0.397
 0.380
 0.286
 0.308
 0.531
 
 A
 0.638
 0.603
 0.620
 0.714
 0.692
 0.468
(+405)
 GG
 55 (37.93)*
 97 (46,7)
 46 (39.31)
 9 (32.14)
 15 (28.9)
 7 (43.8)
 
 GC
 51 (35.17)
 92 (44.4)
 42 (35.89)
 9 (32.14)
 21 (40.4)
 6 (37.5)
 
 CC
 39 (26.90)
 18 (8.9)
 29 (24.78)
 10 (35.71)
 16 (30.7)
 3 (18.8)
 
 G
 0.555*
 0.688
 0.573
 0.482
 0.490
 0.625
 
 C
 0.445
 0.311
 0.427
 0.518
 0.510
 0.375
(+936)
 CC
 101 (69.65)
 168 (81.1)
 83 (70.94)
 18 (64.28)
 41 (78.8)
 12 (75)
 
 CT
 38 (26.21)
 38 (18.3)
 30 (25.64)
 8 (28.57)
 11 (21.1)
 2 (12.5)
 
 TT
 6 (4.14)**
 1 (0.6)
 6 (3.41)
 2 (7.14)
 0
 2 (12.5)****
 
 C
 0.828
 0.903
 0.838
 0.786
 0.894
 0.810
  T 0.172** 0.097 0.179 0.214 0.106 0.190

*Homozygous GG genotype and G allele were significantly higher in AMD patients than in controls [(OR: 3.86, 95%CI [2.03 - 7.42], p = 5 × 10−6 and OR: 1.79, 95%CI [1.3 - 2.48], p = 2 × 10−4 respectively)].

**Homozygous TT genotype and T allele were significantly higher in AMD patients than in controls [(OR: 8.89, 95%CI [1. 05–198.1], p = 0.021 and OR: 1.95, 95%CI [1. 22–3.12], p = 0.003 respectively)].

***Homozygous AA (−2578) genotype was statistically associated with good response [(OR: 0.27, 95%CI [0.07- 1.06], p = 0.042)].

****Homozygous TT (+936) genotype was statistically associated with poor response [(OR: 1.61, 95%CI [0.31-8.28], p = 0.014].